Edgewise Therapeutics, Inc. (EWTX) /
The profitability of Edgewise Therapeutics, Inc. over the past 6 years
Chart Edgewise Therapeutics, Inc.: operating income, net income, fiscal 2020–2025 Open the chart →Edgewise Therapeutics, Inc. reported a net loss of $167.79M in fiscal 2025, the latest fiscal year on file. That year it had an operating loss of $191.41M. It reported a loss in all 6 years shown.
Year by year
| Fiscal year | Operating income | Net income |
|---|---|---|
| 2025ended Dec 31, 2025 | -$191.41M | -$167.79M |
| 2024ended Dec 31, 2024 | -$158.83M | -$133.81M |
| 2023ended Dec 31, 2023 | -$114.36M | -$100.16M |
| 2022ended Dec 31, 2022 | -$71.66M | -$67.64M |
| 2021ended Dec 31, 2021 | -$43.22M | -$42.81M |
| 2020ended Dec 31, 2020 | -$17.19M | -$17.12M |
Fiscal years as Edgewise Therapeutics, Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Edgewise Therapeutics, Inc.
- The cash flow of Edgewise Therapeutics, Inc.
- The debt of Edgewise Therapeutics, Inc.
- All of Edgewise Therapeutics, Inc.'s financials, charted
Companies of a similar size
- BBWIBATH & BODY WORKS, INC.
- KNTKKINETIK HOLDINGS INC.
- ARQTARCUTIS BIOTHERAPEUTICS, INC.
- FRSHFreshworks Inc.
- BYNDBEYOND MEAT, INC.
Not investment advice. This page shows what Edgewise Therapeutics, Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.